Since March 2017 dba Fabric Genomics, - formerly Omicia, Inc.- the firm has re-branded itself to signal launch of fully-integrated and comprehensive genomic data analysis platform for all NGS testing. The firm is developing scalable and integrated informatics systems to interpret human genome sequences for research and clinical applications -- unlocking individualized medicine by translating data derived from whole-genome sequencing into actionable information for researchers and clinicians. Headquartered in Oakland, CA with offices in the U.K., Seattle, Salt Lake City, and Boston, Omicia was founded by scientists and industry veterans in bioinformatics, genomics and diagnostics. The firm maintains a comprehensive database of information about genetic variations related to health conditions and is pioneering new informatics approaches that enhance the power of predictive and preventive medicine. The firm is pioneering new informatics approaches that power next-gen sequencing applications for clinical testing, translational research, and drug development. Omicia's Opal⢠platform integrates genome analysis algorithms and automated clinical annotations, enabling labs to identify and report on disease-causing genes with unprecedented accuracy and efficienc
